Figure 2. Minimal Residual Disease (MRD)–Negative Complete Remission (CR) and Time to Disease Progression (TTP) by Age and Cytogenetic Risk.

Deep and sustained MRD-negative responses and prolonged TTP after treatment with a drug regimen of carfilzomib, lenalidomide, and dexamethasone with lenalidomide maintenance therapy occurred irrespective of age group or adverse cytogenetic risk factors. This depiction of TTP for important myeloma subgroups of age and poor cytogenetic risk shows no difference in hazard ratios (HRs) for TTP for either subgroup. Patients older than 65 years derived a clinical benefit similar to that of younger patients in terms of MRD-negative CR and TTP. Moreover, patients with myeloma who had high cytogenetic risk factors of 17p deletion or translocations of (4;14), (14;16), and (14;20) derived the same levels of deep response and prolonged progression-free duration as those with standard risk.

^aCalculated using the Fisher exact test.

^bCalculated using the log-rank test.